{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06285240",
            "orgStudyIdInfo": {
                "id": "1167-007"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-1167-007",
                    "type": "OTHER",
                    "domain": "Merck ID"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)",
            "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "efficacy-and-safety-of-mk-in-participants-with-alzheimer-s-disease-dementia-taking-stable-donepezil-treatment-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09-20",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09-20",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-22",
            "studyFirstSubmitQcDate": "2024-02-22",
            "studyFirstPostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer's Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Panel A participants will receive a loading dose of MK-1167 6 mg or matching Placebo on Days 1 to 7 followed by once daily (QD) dosing of MK-1167 3 mg or matching Placebo for 14 consecutive days (Days 8 to 21). Panel B participants will receive QD dosing of MK-1167 6 mg or matching Placebo for Days 1 to 31. Panel B will be initiated following review of safety and tolerability data from Panel A.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 28,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "MK-1167 Panel A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 6 mg MK-1167 oral loading doses QD Days 1 to 7, followed by 3 mg MK-1167 oral maintenance doses QD Days 8 to 21. Participants also receive 10 mg oral Donepezil on Days -3 to 21.",
                    "interventionNames": [
                        "Drug: MK-1167",
                        "Drug: Donepezil"
                    ]
                },
                {
                    "label": "Placebo Panel A",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants receive placebo to MK-1167 oral QD from Days 1 to 21. Participants also receive 10 mg oral Donepezil QD on Days -3 to 21",
                    "interventionNames": [
                        "Drug: Donepezil",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "MK-1167 Panel B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 6 mg MK-1167 oral doses QD Days 1 to 31. Participants also receive 10 mg oral Donepezil on Days -3 to 31.",
                    "interventionNames": [
                        "Drug: MK-1167",
                        "Drug: Donepezil"
                    ]
                },
                {
                    "label": "Placebo Panel B",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants receive placebo to MK-1167 oral QD from Days 1 to 31. Participants also receive 10 mg oral Donepezil QD on Days -3 to 31.",
                    "interventionNames": [
                        "Drug: Donepezil",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "MK-1167",
                    "description": "1 mg and 5 mg oral capsules",
                    "armGroupLabels": [
                        "MK-1167 Panel A",
                        "MK-1167 Panel B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Donepezil",
                    "description": "10 mg oral tablets",
                    "armGroupLabels": [
                        "MK-1167 Panel A",
                        "MK-1167 Panel B",
                        "Placebo Panel A",
                        "Placebo Panel B"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "MK-1167 matching placebo administered oral capsules",
                    "armGroupLabels": [
                        "Placebo Panel A",
                        "Placebo Panel B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants experiencing an Adverse Event (AE)",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.",
                    "timeFrame": "Up to approximately 7 weeks"
                },
                {
                    "measure": "Number of participants discontinuing study treatment due to an AE",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinue study treatment due to an AE will be reported.",
                    "timeFrame": "Up to approximately 4 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Area Under the Plasma Concentration-Time Curve from Dosing to 24 Hours Postdose (AUC0-24) of MK-1167",
                    "description": "AUC0-24 is a measure of the total amount of drug in the plasma from the dose to Hour 24.",
                    "timeFrame": "At designated time points up to day 31"
                },
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of MK-1167",
                    "description": "Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.",
                    "timeFrame": "At designated time points up to day 31"
                },
                {
                    "measure": "Plasma Concentration at 24 hours postdose (C24)",
                    "description": "Plasma concentration of MK-1167 at 24 hours (C24) will be reported.",
                    "timeFrame": "At designated time points up to day 31"
                },
                {
                    "measure": "Time to Reach Maximum Plasma Concentration (Tmax) of MK-1167",
                    "description": "Tmax is a measure of the time to reach the maximum concentration in plasma after the drug dose.",
                    "timeFrame": "At designated time points up to day 51"
                },
                {
                    "measure": "Apparent Terminal Half-Life (t\u00bd) of MK-1167",
                    "description": "Apparent t\u00bd is the time required for a given drug concentration in the plasma to decrease by 50%.",
                    "timeFrame": "At designated time points up to day 51"
                },
                {
                    "measure": "Oral Clearance (CL/F) of MK-1167 from Plasma",
                    "description": "CL/F is defined as the rate at which MK-6552 is completely removed from plasma.",
                    "timeFrame": "At designated time points up to day 51"
                },
                {
                    "measure": "Apparent Volume of Distribution (Vz/F) of MK-1167",
                    "description": "Vz/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.",
                    "timeFrame": "At designated time points up to day 51"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Reports a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before Screening, that is either corroborated by an informant who knows the subject well or is documented in medical records\n* Meets the criteria for a diagnosis of probable Alzheimer's disease (AD) based on the National Institute of Neurological and Communicative Disorders - Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD\n* Is receiving donepezil 10 mg daily for symptomatic treatment of cognitive impairment associated with AD. The dose level must be stable for at least 2 months prior to Screening. If receiving donepezil via a transdermal system (ie, patch), it should be a 10-mg/day dose and should switch prescription to a 10-mg oral daily dose, before enrollment\n* Has a reliable and competent trial partner/caregiver who has a close relationship with the participant, has face-to-face contact at least 3 days a week for a minimum of 6 waking hours a week, and is willing to accompany the participant, if desired, to study visits\n\nExclusion Criteria:\n\n* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases that are not under medical control over the past 2 months.\n* Has evidence of a clinically relevant or unstable psychiatric disorder, based on DSM-5 criteria, or has a history of clinically significant psychiatric disorder in the last 5 years. Generalized anxiety disorder, and/or insomnia under good control for \u2265 2 months on stable medical therapy may not be exclusionary.\n* History of cancer (malignancy). Participants with adequately treated disease deemed as \"cured,\" or who, in the opinion of the study investigator, are highly unlikely to sustain a recurrence for the duration of the study, may be enrolled at the discretion of the investigator and Sponsor.\n* History of significant multiple and/or severe allergies (eg, food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or nonprescription drugs or food.\n* Had a major surgery and/or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.\n* Unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to administration of the initial dose of study intervention, throughout the study, until the poststudy visit. There may be certain protocol-specified medications that are permitted.\n* The participant is a smoker and/or has used nicotine or nicotine-containing products (eg, nicotine patch and electronic cigarette) within 3 months of screening.\n* Consumes greater than 3 servings of alcoholic beverages per day. Participants who consume 4 servings of alcoholic beverages per day may be enrolled at the discretion of the investigator.\n* The participant is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 2 years.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "50 Years",
            "maximumAge": "90 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Velocity Clinical Research, Hallandale Beach ( Site 0001)",
                    "status": "RECRUITING",
                    "city": "Hallandale Beach",
                    "state": "Florida",
                    "zip": "33009",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "954-455-5757"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.9812,
                        "lon": -80.14838
                    }
                },
                {
                    "facility": "CenExel iResearch, LLC ( Site 0003)",
                    "status": "COMPLETED",
                    "city": "Decatur",
                    "state": "Georgia",
                    "zip": "30030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.77483,
                        "lon": -84.29631
                    }
                },
                {
                    "facility": "CenExel iResearch, LLC ( Site 0004)",
                    "status": "RECRUITING",
                    "city": "Savannah",
                    "state": "Georgia",
                    "zip": "31405",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "912-744-0800"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08354,
                        "lon": -81.09983
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "http://www.merckclinicaltrials.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077265",
                    "term": "Donepezil"
                }
            ],
            "ancestors": [
                {
                    "id": "D000002800",
                    "term": "Cholinesterase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018678",
                    "term": "Cholinergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018697",
                    "term": "Nootropic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1721",
                    "name": "Donepezil",
                    "asFound": "Prediction",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6040",
                    "name": "Cholinesterase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20758",
                    "name": "Cholinergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20774",
                    "name": "Nootropic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "NootAg",
                    "name": "Nootropic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}